Cardiovascular Deal Benchmarks
Benchmark deal terms across heart failure, ATTR cardiomyopathy, pulmonary arterial hypertension, and hypertension. Cardiovascular deals have seen renewed interest with novel mechanisms and gene therapy approaches. Benchmarks derived from 237 verified transactions.
237
Total Deals
$226M
Avg Upfront
6
Deal Types
90%
Terms Disclosed
Deal Structure Distribution
119
license
56
acquisition
39
collaboration
13
option
8
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Atavistik Bio → Roche | collaboration | $70M | $2.0B | Sep 2026 |
Ionis Pharmaceuticals → Royalty Pharma pelacarsen / Spinraza | other | $500M | $500M | Sep 2026 |
Milestone Pharmaceuticals → Everest Medicines CARDAMYST (etripamil) | license | $30M | $50M | Sep 2026 |
Hanmi Pharm → Genentech HM17321 | license | $190M | $2.3B | Aug 2026 |
Chiesi → Gossamer Bio seralutinib | license | — | — | Aug 2026 |
Sino Biopharmaceutical → AstraZeneca TQC3721 | license | $200M | $1.9B | Jul 2026 |
AirNexis → Haisco dual PDE3/4 inhibitor | license | $40M | — | Jun 2026 |
Jiangsu Hengrui → GSK HRS-9821 | option | $500M | $12.5B | Jun 2026 |
scPharmaceuticals → MannKind scPharmaceuticals subcutaneous cardiology/diuresis products | acquisition | $303M | $303M | Jun 2026 |
Tanabe Pharma Corporation → Mineralys Therapeutics, Inc. lorundrostat | license | $200M | $465M | Jun 2026 |
Benchmark Your Cardiovascular Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 237 verified cardiovascular transactions.
Cardiovascular Deal Benchmarking FAQ
What is driving renewed deal activity in cardiovascular drugs?
Novel mechanisms such as cardiac myosin inhibitors, gene therapies for inherited cardiomyopathies, and RNA-based approaches for ATTR have revitalized cardiovascular deal-making. The success of SGLT2 inhibitors in heart failure also validated the crossover between metabolic and CV indications, attracting new entrants.
How do ATTR cardiomyopathy deal structures compare to other CV deals?
ATTR deals command premium valuations due to the validated biology (following tafamidis approval) and large addressable market in wild-type ATTR. Gene silencing and editing approaches for hereditary ATTR have seen upfronts of $100M+ with total deal values exceeding $1B, significantly above typical cardiovascular deal ranges.
What cardiovascular deal terms should licensors benchmark against?
Cardiovascular licensing deals typically feature upfronts of $20M-$150M depending on stage and mechanism novelty. Royalties range 10-18% for licensed products. Co-development structures are common for late-stage assets, while gene therapy approaches tend to use milestone-heavy structures reflecting the longer path to market.